

---

# Guidance for Industry

## Warnings and Precautions, Contraindications, and Boxed Warning Sections of Labeling for Human Prescription Drug and Biological Products — Content and Format

### *DRAFT GUIDANCE*

**This guidance document is being distributed for comment purposes only.**

Comments and suggestions regarding this draft document should be submitted within 90 days of publication in the *Federal Register* of the notice announcing the availability of the draft guidance. Submit comments to the Division of Dockets Management (HFA-305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852. All comments should be identified with the docket number listed in the notice of availability that publishes in the *Federal Register*.

For questions regarding this draft document contact (CDER) Janet Norden at 301-796-2270, or (CBER) Toni Stifano at 301-827-6190.

**U.S. Department of Health and Human Services  
Food and Drug Administration  
Center for Drug Evaluation and Research (CDER)  
Center for Biological Evaluation and Research (CBER)**

**January 2006  
Labeling**

# Guidance for Industry

## **Warnings and Precautions, Contraindications, and Boxed Warning Sections of Labeling for Human Prescription Drug and Biological Products — Content and Format**

*Additional copies are available from:*

*Office of Training and Communications  
Division of Drug Information, HFD-210  
5600 Fishers Lane  
Rockville, MD 20857  
(Tel) 301-827-4573*

*(Internet) <http://www.fda.gov/cder/guidance/index.htm>*

*or*

*Office of Communication, Training and  
Manufacturers Assistance, HFM-40  
Center for Biologics Evaluation and Research  
Food and Drug Administration  
1401 Rockville Pike, Rockville, MD 20852-1448  
(Tel) 800-835-4709 or 301-827-1800  
(Internet) <http://www.fda.gov/cber/guidelines.htm>.*

**U.S. Department of Health and Human Services  
Food and Drug Administration  
Center for Drug Evaluation and Research (CDER)  
Center for Biologics Evaluation and Research (CBER)**

**January 2006  
Labeling**

*Contains Nonbinding Recommendations*

*Draft — Not for Implementation*

**TABLE OF CONTENTS**

<b>I.</b>	<b>INTRODUCTION.....</b>	<b>1</b>
<b>II.</b>	<b>WARNINGS AND PRECAUTIONS SECTION (§ 201.57(c)(6)).....</b>	<b>2</b>
<b>A.</b>	<b>Adverse Reactions and Information to Include .....</b>	<b>2</b>
	1. <i>Observed Adverse Reactions</i> .....	2
	2. <i>Expected Adverse Reactions</i> .....	2
	3. <i>Additional Considerations</i> .....	3
	4. <i>Adverse Reactions Associated with Unapproved Uses</i> .....	4
	5. <i>Drug Interactions</i> .....	4
	6. <i>Monitoring</i> .....	4
<b>B.</b>	<b>Information to Provide .....</b>	<b>4</b>
<b>C.</b>	<b>Format.....</b>	<b>5</b>
	1. <i>Subheadings</i> .....	5
	2. <i>Order of Adverse Reactions</i> .....	6
	3. <i>Emphasis in Text</i> .....	6
	4. <i>Cross-Referencing</i> .....	6
<b>III.</b>	<b>CONTRAINDICATIONS SECTION (§ 201.57(c)(5)) .....</b>	<b>6</b>
<b>A.</b>	<b>When to Contraindicate .....</b>	<b>6</b>
	1. <i>Observed Adverse Reactions</i> .....	6
	2. <i>Expected Adverse Reactions</i> .....	7
	3. <i>Likely Clinical Situations</i> .....	7
<b>B.</b>	<b>Information to Provide .....</b>	<b>8</b>
<b>C.</b>	<b>Format.....</b>	<b>8</b>
	1. <i>Subheadings</i> .....	8
	2. <i>Order of Contraindications</i> .....	8
	3. <i>Text Emphasis</i> .....	9
<b>IV.</b>	<b>BOXED WARNING (§ 201.57(c)(1)) .....</b>	<b>9</b>
<b>A.</b>	<b>When to Use a Boxed Warning.....</b>	<b>9</b>
<b>B.</b>	<b>Information to Provide .....</b>	<b>10</b>
<b>C.</b>	<b>Format.....</b>	<b>10</b>
	<b>GLOSSARY.....</b>	<b>11</b>

1  
2  
3  
4  
5  
6  
7  
8  
9

## Guidance for Industry<sup>1</sup>

### Warnings and Precautions, Contraindications, and Boxed Warning Sections of Labeling for Human Prescription Drug and Biological Products — Content and Format<sup>2</sup>

This draft guidance, when finalized, will represent the Food and Drug Administration's (FDA's) current thinking on this topic. It does not create or confer any rights for or on any person and does not operate to bind FDA or the public. An alternative approach may be used if such approach satisfies the requirements of the applicable statutes and regulations. If you want to discuss an alternative approach, contact the FDA staff responsible for implementing this guidance. If you cannot identify the appropriate FDA staff, call the appropriate number listed on the title page of this guidance.

10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20

#### I. INTRODUCTION

This guidance is intended to assist applicants and reviewers in drafting the WARNINGS AND PRECAUTIONS, CONTRAINDICATIONS, and BOXED WARNING sections of labeling, as described in the final rule amending the requirements for the content and format of labeling for human prescription drug and biological products (21 CFR 201.56 and 201.57).<sup>3</sup> The recommendations in this guidance are intended to help ensure that the labeling is clear, useful, informative, and to the extent possible, consistent in content and format.

This guidance provides recommendations on the following:

21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34

- How to decide which adverse reactions are significant enough to warrant inclusion in the WARNINGS AND PRECAUTIONS section; what information to include when describing those adverse reactions; and how to organize the section

<sup>1</sup> This guidance has been prepared by the Medical Policy Coordinating Committees in the Center for Drug Evaluation and Research (CDER) and Center for Biologics Evaluation and Research (CBER) at the Food and Drug Administration.

<sup>2</sup> This guidance applies to drugs, including biological drug products. For the purposes of this guidance, *drug product* or *drug* will be used to refer to human prescription drug and biological products that are regulated as drugs.

<sup>3</sup> See the final rule “Requirements on Content and Format of Labeling for Human Prescription Drug and Biological Products” published in the *Federal Register* in January 2006.

## ***Contains Nonbinding Recommendations***

*Draft — Not for Implementation*

- 35 • What situations warrant a contraindication; what information to provide in those  
36 situations when the use of the product is contraindicated; and how to organize the  
37 CONTRAINDICATIONS section
- 38 • When to include a boxed warning; and what information to include in the BOXED  
39 WARNING section

40  
41 FDA's guidance documents, including this guidance, do not establish legally enforceable  
42 responsibilities. Instead, guidances describe the Agency's current thinking on a topic and should  
43 be viewed only as recommendations, unless specific regulatory or statutory requirements are  
44 cited. The use of the word *should* in Agency guidances means that something is suggested or  
45 recommended, but not required.

46

### **II. WARNINGS AND PRECAUTIONS SECTION (§ 201.57(c)(6))**

47

#### **A. Adverse Reactions and Information to Include**

48

49

50

51

52

53

54

55

56

57

##### *1. Observed Adverse Reactions*

This section includes clinically significant adverse reactions observed in association with the use of a drug for which there is reasonable evidence of a causal association between the drug and the adverse reaction (a causal relationship need not have been established):

58

59

60

61

62

63

64

65

66

67

68

69

70

71

72

73

74

##### ***IF***

- The adverse reaction is serious (see glossary for definition of serious adverse reaction).

##### ***OR***

- The adverse reaction does not meet the definition of a serious adverse reaction, but is still considered clinically significant (*otherwise clinically significant*). Adverse reactions that are considered *otherwise clinically significant* could include:

- Adverse reactions that require discontinuation, dosage or regimen adjustment, or addition of another drug

- Adverse reactions that could be prevented or managed with appropriate patient selection or avoidance of concomitant therapy

- Adverse reactions that significantly affect patient compliance

70

71

72

73

74

- The product interferes with a laboratory test.

##### *2. Expected Adverse Reactions*

There are circumstances in which an adverse reaction can be expected to occur with a drug, despite its not having been observed with that drug, based on observations from

## *Contains Nonbinding Recommendations*

*Draft — Not for Implementation*

75 other members of the drug class or animal studies. An expected adverse reaction may not  
76 be observed, for example, in clinical trials for newer drugs in a class where the trials are  
77 designed to exclude populations that were determined to be vulnerable to the adverse  
78 reaction with earlier members of the drug class.

79  
80 The WARNINGS AND PRECAUTIONS section includes adverse reactions that are  
81 expected to occur with a drug, but have yet to be observed if:

- 82  
83 • The reaction is *serious* or *otherwise clinically significant* as discussed above

84  
85 ***AND EITHER***

- 86 • Based on what is known about the pharmacology, chemistry, or class of the drug, it  
87 appears likely that the adverse reaction will occur with the drug.

88 ***OR***

- 89 • Animal data raise substantial concern about the potential for occurrence of the  
90 adverse reaction in humans (e.g., animal data demonstrating that a drug has  
91 teratogenic effects).

92 In these cases, the labeling should acknowledge that the adverse reaction has not been  
93 observed, but may be expected to occur.

94  
95 **3. *Additional Considerations***

96  
97 The following factors should also be considered in determining whether to include an  
98 adverse reaction in the WARNINGS AND PRECAUTIONS section of labeling:

- 99  
100 • Indication

101  
102 The relative seriousness of the disease or condition for which a drug is indicated will  
103 influence whether an adverse reaction would be considered clinically significant and thus  
104 appropriate for inclusion in the WARNINGS AND PRECAUTIONS section. For  
105 example, for a drug intended to treat a minor, self-limiting condition (e.g., allergic  
106 rhinitis, cosmetic conditions, transient insomnia), a nonserious adverse reaction (e.g.,  
107 nausea, pruritis, alopecia) may be considered clinically significant and, therefore,  
108 appropriate for inclusion in the section. For a drug intended to treat a serious or life-  
109 threatening condition (e.g., cancer), the same adverse reaction may be considered much  
110 less clinically significant and not appropriate for inclusion in the section.

## *Contains Nonbinding Recommendations*

*Draft — Not for Implementation*

111  
112  
113  
114  
115  
116  
117  
118  
119  
120  
121  
122  
123  
124  
125  
126  
127  
128  
129  
130  
131  
132  
133  
134  
135  
136  
137  
138  
139  
140  
141  
142  
143  
144  
145  
146  
147  
148  
149  
150  
151  
152  
153  
154  
155  
156

- Incidence

Typically, the nature of an adverse reaction and a drug's indication are the most influential factors in determining whether an adverse reaction should be included in the WARNINGS AND PRECAUTIONS section. In some cases, however, the absolute risk or rate of an adverse reaction can be an important factor when deciding whether to include the reaction in this section (e.g., when the risk or rate is high).

- Ability to Manage or Prevent an Adverse Reaction

The ability to manage or prevent an adverse reaction through patient monitoring, proper dose selection or titration, or avoidance of concomitant therapy can also be an important factor in deciding whether to discuss an adverse reaction in the WARNINGS AND PRECAUTIONS section.

#### *4. Adverse Reactions Associated with Unapproved Uses*

FDA may require a specific warning relating to an unapproved use if the drug is commonly prescribed for a disease or condition and such usage is associated with a clinically significant risk or hazard (§ 201.57(c)(6)(i)). Clinically significant adverse reactions that appear to be linked primarily to an unapproved use of a drug (e.g., use for a disease, condition, or population not included in the INDICATIONS AND USE section, use of an unapproved dose or regimen) should be identified and discussed in the WARNINGS AND PRECAUTIONS section. The discussion should include a statement indicating that safety and effectiveness have not been established in that setting and that the use is not approved by FDA.

#### *5. Drug Interactions*

The WARNINGS AND PRECAUTIONS section should include a discussion of any known or predicted drug interactions with serious or otherwise clinically significant outcomes, with a cross-reference to any additional information in the DRUG INTERACTIONS or CLINICAL PHARMACOLOGY sections.

#### *6. Monitoring*

The WARNINGS AND PRECAUTIONS section must identify any laboratory tests helpful in following the patient's response or in identifying possible adverse reactions (§ 201.57(c)(6)(iii)), and, if appropriate, information about the frequency of testing and expected ranges of normal and abnormal values.

### **B. Information to Provide**

The WARNINGS AND PRECAUTIONS section should contain the following information for each adverse reaction, if such information is known:

## Contains Nonbinding Recommendations

Draft — Not for Implementation

- 157
- 158
- 159
- A description of the adverse reaction and outcome (e.g., time to resolution, significant sequelae)
  - An estimate of risk or adverse reaction rate<sup>4</sup>
  - A discussion of known risk factors for the adverse reaction (e.g., age, gender, race, comorbid conditions, dose, duration of use, coadministered drugs)
  - A discussion of steps to take to reduce the risk of, decrease the likelihood of, shorten the duration of, or minimize the severity of an adverse reaction. These steps could include, for example, necessary evaluation prior to use, titration and other kinds of dose adjustment, monitoring during dose adjustment or prolonged use, avoidance of other drugs or substances, or special care during comorbid events (e.g., dehydration, infection)
  - A discussion of how to treat, or otherwise manage, an adverse reaction that has occurred
- 160
- 161
- 162
- 163
- 164
- 165
- 166
- 167
- 168
- 169
- 170

171 Although the following issues would typically be discussed elsewhere in labeling, they  
172 can also be mentioned in the WARNINGS AND PRECAUTIONS section when such  
173 information would help prescribers understand the clinical significance of an adverse  
174 reaction:

- 175
- A discussion of the mechanism of the adverse reaction
  - The source of information about the adverse reaction (e.g., it may be informative to know whether the information is from clinical trials or postmarketing reports, or whether an adverse reaction was seen only in foreign experience with the drug)
- 176
- 177
- 178
- 179

180 The information and advice provided in this section should be reasonably qualified,  
181 where appropriate, to convey whatever uncertainties may exist about judgments and  
182 conclusions made (e.g., concerning causality assessments, estimated adverse reaction  
183 rates, and value of proposed monitoring).

### 184 **C. Format**

#### 185 *1. Subheadings*

186 FDA recommends that each adverse reaction, syndrome, or constellation of reactions  
187 (e.g., thrombotic events, hemorrhagic events) included in the WARNINGS AND  
188 PRECAUTIONS section have its own subheading. There would ordinarily be no reason  
189

---

<sup>4</sup> When the risk for an adverse reaction is highest during early exposure, crude risk (# of adverse reactions/# patients exposed) may be the best estimate. For adverse reactions that occur after prolonged exposure, there should be an adjustment for duration of exposure by use of either overall exposed person time if the risk is constant over time, or by calculation of cumulative incidence for a specified exposure time in a survival analysis.



## *Contains Nonbinding Recommendations*

*Draft — Not for Implementation*

193 to further subcategorize adverse reactions (e.g., separating observed and expected adverse  
194 reactions by placing them under different subheadings).

195  
196 **2. *Order of Adverse Reactions***

197  
198 The order in which adverse reactions are presented should reflect the relative public  
199 health significance of the adverse reactions. Factors to consider include the relative  
200 seriousness of the adverse reaction, the ability to prevent or mitigate the adverse reaction,  
201 the likelihood of occurrence, and the size of the population that is potentially affected. In  
202 general, the relative seriousness of the adverse reaction and the ability to prevent or  
203 mitigate it weigh more heavily than the likelihood of occurrence or the size of the  
204 affected population.

205  
206 **3. *Emphasis in Text***

207  
208 Bolded text, or other emphasis, can be used to highlight particular adverse reactions or  
209 parts of the discussion of particular adverse reactions (e.g., steps to be taken to avoid a  
210 problem, subpopulations at particular risk). Emphasis should be used sparingly so that its  
211 impact is not diminished. When information is to be emphasized, also consider whether  
212 that information should be in a boxed warning (see section IV on BOXED WARNING  
213 section).

214  
215 **4. *Cross-Referencing***

216  
217 Information discussed in the WARNINGS AND PRECAUTIONS section often is  
218 discussed or mentioned in other sections of the labeling (e.g., ADVERSE REACTIONS,  
219 DOSAGE AND ADMINISTRATION, DRUG INTERACTIONS). Information  
220 appearing in other locations should be appropriately cross-referenced.

221  
222  
223 **III. CONTRAINDICATIONS SECTION (§ 201.57(c)(5))**

224  
225 **A. When to Contraindicate**

226  
227 A drug should be contraindicated only in those clinical situations for which the risk from  
228 use clearly outweighs any possible therapeutic benefit. Only known hazards, and not  
229 theoretical possibilities, must be listed. If there are no known contraindications for a  
230 drug, this section must state “None.”

231  
232 **1. *Observed Adverse Reactions***

233  
234 For observed adverse reactions, the following would ordinarily be reason to  
235 contraindicate a drug:  
236

## *Contains Nonbinding Recommendations*

*Draft — Not for Implementation*

- 237
- 238
- 239
- The risk of the adverse reaction in the clinical situation to which the contraindication will apply, based on both likelihood and severity of the adverse reaction, outweighs any potential benefit to the patient.

240 **AND**

- 241
- 242
- The causal relationship between exposure to the drug and the adverse reaction is well established.

243

244 2. *Expected Adverse Reactions*

245

246 Adverse reactions that are expected to occur when a drug is used in a specific clinical  
247 situation can be the basis for a contraindication.<sup>5</sup> The following would ordinarily be  
248 reason to contraindicate a drug on the basis of an expected adverse reaction.

249

250 The risk of the adverse reaction in the clinical situation to which the contraindication will  
251 apply, based on both likelihood and severity of the adverse reaction, outweighs any  
252 potential benefit to the patient

253 **AND EITHER**

- 254
- 255
- Based on what is known about the pharmacology, chemistry, or class of the drug, it appears highly likely that the adverse reaction will occur with the drug.

256 **OR**

- 257
- 258
- 259
- Animal data raise substantial concern about the potential for occurrence of the adverse reaction in humans (e.g., animal data demonstrating that a drug has teratogenic effects).

260

261 The labeling should acknowledge that the adverse reaction has not yet been observed, but  
262 is expected to occur.

263

264 3. *Likely Clinical Situations*

265

266 A contraindication usually involves one or more of the following clinical situations:

267

- 268
- 269
- 270
- Comorbid condition or coexistent physiological state (e.g., existing hepatic disease, renal disease, congenital long QT syndrome, hypokalemia, pregnancy or childbearing potential, CYP 2D6 poor metabolizer<sup>6</sup>)

271

- 272
- Demographic risk factor (e.g., age, sex, race, genetic vulnerability)

---

<sup>5</sup> Expected adverse reactions are distinguishable from “theoretical possibilities” because there are data (e.g., from class, chemistry, animal studies) to support the expected adverse reaction.

<sup>6</sup> Use of a particular drug in a patient with a slow metabolizer status would be contraindicated only if there were no way to lower the dose to adjust for the compromised metabolic state.

## *Contains Nonbinding Recommendations*

*Draft — Not for Implementation*

- 273  
274  
275  
276  
277  
278  
279  
280
- The risks of the drug are such that the drug should never be used in a selected subset of the larger population with a disease<sup>7</sup>
  - Coadministered drug where the combination is dangerous (e.g., MAO inhibitor and sympathomimetic drug, a drug known to prolong the QT interval and a drug known to interfere with the metabolism of that drug)<sup>8</sup>

281  
282  
283  
284  
285

Contraindications based on drug interactions with serious outcomes should be described in the CONTRAINDICATIONS section and cross-referenced to more detailed information in the DRUG INTERACTIONS or CLINICAL PHARMACOLOGY sections.

### **B. Information to Provide**

286  
287  
288  
289

For each listed contraindication, provide the following information:

- 290  
291  
292  
293  
294
- Brief description of the contraindicated situation or scenario, including any pertinent demographic or identifiable predisposing characteristics
  - Description of anticipated consequences of the contraindicated use

### **C. Format**

#### *1. Subheadings*

295  
296  
297  
298  
299  
300

FDA recommends that each contraindication be identified by its own subheading.

#### *2. Order of Contraindications*

301  
302  
303  
304  
305  
306

The order in which contraindications are presented should reflect the relative public health significance of the listed contraindications. Factors to consider include the likelihood of occurrence and the size of the population that is potentially affected.

---

<sup>7</sup> The INDICATIONS AND USAGE section must contain information about use of the drug when safety considerations are such that the drug should be reserved for certain patients (e.g., patients with severe disease) or situations (e.g., patients refractory to other drugs) (§ 201.57(c)(2)(i)(B) and (E)). In rare cases, when the risks of the drug clearly outweigh any possible therapeutic benefit and the drug should never be used in a selected patient subset, a contraindication for use of the drug in that subset should also be described in the CONTRAINDICATIONS section.

<sup>8</sup> There should be consistency across labeling for contraindicated products (i.e., if use of drug A with drug B is contraindicated in the labeling for drug A, the use of drug B with drug A should be contraindicated in the labeling for drug B). For drugs that are regulated in different reviewing divisions, there should be cross-divisional coordination and agreement on contraindicated coadministration of drugs.

## *Contains Nonbinding Recommendations*

*Draft — Not for Implementation*

307 3. *Text Emphasis*

308

309 Bolded text, or other emphasis, can be used to highlight particular contraindicated  
310 situations or parts of the discussions of these situations. Emphasis should be used  
311 sparingly so that its impact is not diminished. When information is to be emphasized,  
312 also consider whether that information should be in a boxed warning (see BOXED  
313 WARNING below).

314

315

316 **IV. BOXED WARNING (§ 201.57(c)(1))**

317

318 **A. When to Use a Boxed Warning**

319

320 A boxed warning is ordinarily used to highlight for prescribers one of the following  
321 situations:

322

- 323 • There is an adverse reaction so serious in proportion to the potential benefit from the  
324 drug (e.g., a fatal, life-threatening or permanently disabling adverse reaction) that it is  
325 essential that it be considered in assessing the risks and benefits of using a drug

326 ***OR***

- 327 • There is a serious adverse reaction that can be prevented or reduced in frequency or  
328 severity by appropriate use of the drug (e.g., patient selection, careful monitoring,  
329 avoiding certain concomitant therapy, addition of another drug or managing patients  
330 in a specific manner, avoiding use in a specific clinical situation)

331 ***OR***

- 332 • FDA approved the drug with restrictions to assure safe use because FDA concluded  
333 that the drug can be safely used only if distribution or use is restricted (e.g., under 21  
334 CFR part 314, subpart H, § 314.520 “Approval with restrictions to assure safe use”).

335

336 A boxed warning can also be used in other situations to highlight warning information  
337 that is especially important to the prescriber. Information included in the WARNINGS  
338 AND PRECAUTIONS and CONTRAINDICATIONS sections should therefore be  
339 evaluated to determine whether it should also be placed in a boxed warning.

340

341 Boxed warnings are more likely to be based on observed adverse reactions, but there are  
342 instances when a boxed warning based on an expected adverse reaction would be  
343 appropriate. For example, a contraindication during pregnancy based on evidence in  
344 humans that drugs in a pharmacologic class pose a serious risk of developmental toxicity  
345 during that time would usually be in a boxed warning for all drugs in that class, even  
346 those in which the adverse reaction has not been seen.

347

348 A boxed warning can also be considered for a drug that has important risk/benefit  
349 information that is unique among drugs in a drug class (e.g., to note that a drug is the

## *Contains Nonbinding Recommendations*

*Draft — Not for Implementation*

350 only one in its class to have a particular risk that makes it inappropriate for use as a first  
351 line therapy).

352

### **B. Information to Provide**

354

355 A boxed warning provides a brief, concise summary of the information that is critical for  
356 a prescriber to be aware of, including any restriction on distribution or use. If there is a  
357 more detailed discussion of the concern in either the CONTRAINDICATIONS or  
358 WARNINGS AND PRECAUTIONS section, or any other labeling section that contains  
359 pertinent information (e.g., DOSAGE AND ADMINISTRATION), a cross-reference to  
360 that section must be provided (§ 201.57(c)(1)).

361

### **C. Format**

362

363  
364 FDA recommends the information in the boxed warning be presented in a bulleted format  
365 (or some alternative format, such as subheadings) that helps to make the information  
366 visually accessible.

367

## Contains Nonbinding Recommendations

Draft — Not for Implementation

368  
369  
370  
371  
372  
373  
374  
375  
376  
377  
378  
379  
380  
381  
382  
383  
384  
385  
386  
387  
388  
389  
390  
391  
392  
393  
394  
395

### GLOSSARY

**Adverse Reaction (21 CFR 201.57(c)(7)):** For purposes of prescription drug labeling and this guidance, an *adverse reaction* is an undesirable effect, reasonably associated with the use of a drug, that may occur as part of the pharmacological action of the drug or may be unpredictable in its occurrence. This definition does not include all adverse events observed during use of a drug, only those for which there is some basis to believe there is a causal relationship between the drug and the occurrence of the adverse event.

Adverse reactions may include signs and symptoms, changes in laboratory parameters, and changes in other measures of critical body function, such as vital signs and electrocardiogram (ECG).

**Adverse Event (or adverse experience):** For the purposes of this guidance, an *adverse event* refers to any untoward medical event associated with the use of a drug in humans, whether or not considered drug-related.

**Serious Adverse Reaction:** For purposes of this guidance, the term *serious adverse reaction* refers to any reaction occurring at any dose that results in any of the following outcomes: Death, a life-threatening adverse experience, inpatient hospitalization or prolongation of existing hospitalization, a persistent or significant disability or incapacity, or a congenital anomaly or birth defect. Important medical events that may not result in death, be life-threatening, or require hospitalization may be considered serious adverse drug reactions when, based upon appropriate medical judgment, they may jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the outcomes listed in this definition.